Polycystic ovary syndrome (PCOS) affects roughly 1 in 10 women of reproductive age, yet finding a treatment that addresses more than one symptom at a time remains a real challenge. Weight gain, insulin resistance, irregular periods, and elevated androgens tend to feed into each other, creating a cycle that diet and exercise alone may not break.
That is why GLP-1 receptor agonists, the same class of medications making headlines for weight loss, have caught the attention of researchers and clinicians treating PCOS. Early evidence suggests these drugs may do more than reduce body weight. They appear to improve insulin sensitivity, lower androgen levels, and restore menstrual regularity in some women.
Book a free women’s health consultation with a 1st Optimal provider to find out if GLP-1 therapy could be part of your PCOS management plan.
Below, we break down what the clinical research actually says, compare the GLP-1 medications available today, and outline practical steps for women with PCOS who want to explore this option.
What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone your body produces naturally after eating. GLP-1 signals your pancreas to release insulin, slows gastric emptying so food stays in your stomach longer, and reduces appetite by acting on hunger centers in the brain.
The FDA originally approved GLP-1 medications for type 2 diabetes management and, more recently, for chronic weight management. The most recognized names include:
- Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) - available as a weekly injection or daily oral tablet
- Tirzepatide (brand names: Mounjaro, Zepbound) - a dual GIP/GLP-1 receptor agonist given as a weekly injection
- Liraglutide (brand names: Victoza, Saxenda) - a daily injection and the first GLP-1 studied in PCOS clinical trials
For a deeper look at how these medications work at the cellular level, see our guide on how GLP-1 medications work.
How GLP-1 Medications May Help Women with PCOS
PCOS is not just a reproductive condition. It is, at the root, a metabolic disorder. Up to 70% of women with PCOS have some degree of insulin resistance, which drives weight gain, stimulates excess androgen production, and disrupts ovulation.
GLP-1 receptor agonists target several of these interconnected pathways simultaneously:
- Insulin resistance reduction: GLP-1 medications improve insulin signaling and glucose uptake in tissues. For women with PCOS, this may help break the insulin-androgen cycle where high insulin levels stimulate the ovaries to produce excess testosterone.
- Clinically significant weight loss: Excess weight amplifies every PCOS symptom. GLP-1 medications produce average weight reductions of 15-22% of body weight in clinical trials, reducing visceral fat that drives inflammation and hormonal disruption.
- Androgen lowering: Research shows GLP-1 therapy can reduce total testosterone levels in women with PCOS, which may improve symptoms like acne, excess hair growth, and hair thinning.
- Inflammation modulation: Chronic low-grade inflammation is a feature of PCOS. GLP-1 receptor agonists have demonstrated anti-inflammatory effects that extend beyond weight loss alone.
- Menstrual regularity: By improving insulin sensitivity and reducing weight, GLP-1 medications may help restore regular ovulatory cycles in some women.
If you are unsure whether your symptoms point to a hormonal imbalance, consider getting a full picture through thorough testing before exploring any medication.
What Does the Research Show?
The evidence base for GLP-1 medications in PCOS has grown quickly over the past few years. Here are the most significant findings from published research:
Weight and Body Composition
A 2025 meta-analysis published in Nature Scientific Reports (Tan et al.) pooled data from multiple randomized controlled trials of GLP-1 receptor agonists in women with PCOS. The results showed statistically significant reductions in BMI, body weight, waist circumference, and waist-to-hip ratio compared to control groups (P < 0.0001 in all categories).
A separate clinical study of 27 obese women with PCOS treated with 0.5 mg weekly semaglutide found that roughly 80% achieved at least 5% body weight loss within 3 months. Among those who continued treatment for 6 months, average total weight loss reached 11.5 kg, with mean BMI dropping from 34.4 to 29.4 (PMC, 2023).
Insulin Resistance and Metabolic Markers
The same meta-analysis by Tan et al. found that GLP-1 receptor agonists significantly reduced fasting insulin levels and HOMA-IR scores (a standard measure of insulin resistance) in women with PCOS. Improvements in insulin resistance occurred even in participants who did not achieve major weight loss, suggesting a direct metabolic effect beyond weight reduction.
Testosterone and Androgen Levels
A 2024 meta-analysis published in the Journal of Diabetes and Its Complications (Han et al.) analyzed 4 randomized controlled trials with 176 participants. The pooled results demonstrated a statistically significant reduction in total testosterone (P = 0.03), along with a 5.16 cm decrease in waist circumference (P < 0.00001) and reduced triglycerides (P < 0.00001).
Lower androgen levels may translate to visible improvements in symptoms like hirsutism (excess facial and body hair), hormonal acne, and androgenic alopecia, though more large-scale studies are needed to confirm the extent of these benefits.
Menstrual Regularity and Fertility
In the semaglutide clinical study mentioned above, 80% of participants normalized their menstrual cycles during treatment. While this is a promising signal, current clinical trials, including NCT04876027 and NCT06775093, are actively investigating the effects of GLP-1 receptor agonists on reproductive outcomes in women with PCOS and obesity. Results from these trials will help clarify whether GLP-1 medications meaningfully improve fertility in this population.
For more on the connection between PCOS, insulin resistance, and fertility, see our article on PCOS and its impact on fertility.
Real-World Usage Trends
A Truveta Research analysis of over 1.7 million female patients prescribed semaglutide or tirzepatide between 2021 and 2025 found that GLP-1 prescriptions among women with PCOS jumped from 2.4% to 17.6%, a 637.5% increase. Nearly all PCOS patients receiving these medications also carried an obesity or type 2 diabetes diagnosis, reflecting their current approved indications.
Which GLP-1 Medication Is Best for PCOS?
There is no single “best” GLP-1 for PCOS because the choice depends on individual factors including BMI, metabolic profile, and treatment goals. Here is how the main options compare:
| Feature | Semaglutide | Tirzepatide | Liraglutide |
|---|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP + GLP-1 agonist | GLP-1 agonist |
| Dosing | Weekly injection or daily pill | Weekly injection | Daily injection |
| Average Weight Loss | 15-20% of body weight | Up to 22.5% of body weight | 5-10% of body weight |
| PCOS Clinical Data | Growing (80% menstrual normalization in small study) | Limited but strongest weight/metabolic results | Most studied for PCOS (58% of RCT participants) |
| Key Advantage | Oral option available; strong insulin effect | Dual pathway; highest weight loss potential | Longest track record in PCOS research |
| Availability | Widely available; compounded options exist | Widely available | Widely available |
Bottom line: Liraglutide has the most published PCOS-specific research, but semaglutide and tirzepatide deliver stronger weight loss and metabolic improvements. Many providers now favor semaglutide or tirzepatide for PCOS patients who need significant weight reduction. For a detailed comparison, see our article on semaglutide vs. tirzepatide.
It is important to note that GLP-1 medications are not yet FDA-approved specifically for PCOS. Prescribing them for this condition is considered off-label, though it is a common and increasingly evidence-supported practice.
Not sure which GLP-1 option might fit your situation? Take our free GLP-1 quiz to get a personalized starting point.
GLP-1 Medications vs. Metformin for PCOS
Metformin has been the go-to medication for PCOS-related insulin resistance for decades. So where do GLP-1 medications fit in?
| Factor | Metformin | GLP-1 Medications |
|---|---|---|
| Primary Mechanism | Reduces hepatic glucose production | Mimics GLP-1 hormone; multi-pathway |
| Weight Loss | Modest (2-5%) | Significant (15-22%) |
| Insulin Resistance | Moderate improvement | Significant improvement |
| Androgen Reduction | Moderate | Moderate to significant |
| Menstrual Regularity | Some improvement | Promising early data (80% in one study) |
| Cost | Low (generic available) | Higher (brand; compounded options lower) |
| PCOS Research Base | Extensive (decades) | Growing (5+ years) |
| Common Side Effects | GI upset, diarrhea | Nausea, vomiting (typically temporary) |
Some clinicians now prescribe GLP-1 medications alongside metformin for PCOS patients who need stronger metabolic support. The combination may offer additive benefits, though dedicated combination studies in PCOS populations are still limited. Your provider can help determine whether one or both medications make sense for your situation.
A Functional Medicine Approach: GLP-1 as Part of a Bigger Picture
At 1st Optimal, we view GLP-1 medications as one tool within a broader, root-cause approach to PCOS management, not as a standalone fix.
PCOS involves multiple overlapping systems: hormonal regulation, metabolic function, gut health, inflammation, and stress response. A medication that targets insulin and weight is valuable, but lasting results typically require addressing the full picture.
A functional medicine PCOS protocol might include:
- Advanced diagnostic testing: Standard labs often miss the full scope of PCOS. Panels like the DUTCH hormone test can reveal how your body metabolizes estrogen, progesterone, and testosterone, giving providers a clearer treatment map.
- Gut health optimization: Research increasingly links gut microbiome composition to PCOS severity. Addressing dysbiosis may improve GLP-1 medication effectiveness while supporting overall metabolic health.
- Targeted nutrition: An anti-inflammatory, blood sugar-stabilizing eating pattern supports GLP-1 therapy and may reduce the medication dose needed over time.
- Exercise programming: Resistance training and moderate-intensity cardio can improve insulin sensitivity on their own and amplify the effects of GLP-1 medications. Strength training is also critical to prevent muscle loss during GLP-1 treatment.
- Hormone optimization: Some women with PCOS benefit from concurrent treatment addressing hormone balance, including progesterone support, thyroid optimization, or addressing estrogen dominance.
- Stress and sleep management: Cortisol dysregulation worsens insulin resistance and promotes visceral fat storage, two factors that GLP-1 medications also target. Managing stress creates a stronger foundation for treatment success.
This integrative approach is what sets functional medicine apart from simply prescribing a medication and checking back in 3 months.
Ready to explore a root-cause approach to your PCOS? Schedule a free consultation with a 1st Optimal provider who specializes in women’s hormonal health.
Side Effects and Safety Considerations
GLP-1 medications are generally well-tolerated, but side effects do occur, particularly during the dose escalation phase. The Tan et al. meta-analysis found statistically significant increases in nausea (P = 0.02), vomiting (P = 0.04), and dizziness (P = 0.03) compared to control groups.
Common side effects include:
- Nausea (most common, usually improves after 4-8 weeks)
- Vomiting or diarrhea
- Constipation
- Headache
- Injection site reactions
Serious but rare risks include pancreatitis and gallbladder disease. Women who are pregnant, planning to become pregnant soon, or have a personal or family history of medullary thyroid carcinoma should not use GLP-1 medications.
Most side effects can be managed through slow dose titration and dietary adjustments. For a full breakdown, see our guide on GLP-1 side effects and how to manage them.
Important note for women trying to conceive: GLP-1 medications should be discontinued at least 2 months before planned conception (semaglutide) or 1 month (liraglutide). If improved ovulation leads to unexpected fertility, use reliable contraception while on these medications unless pregnancy is desired and medically supervised.
How to Get GLP-1 Medications for PCOS
Because GLP-1 medications are not specifically FDA-approved for PCOS, the access pathway requires some navigation. Here is what you need to know:
Off-Label Prescribing
A licensed medical provider can prescribe GLP-1 medications off-label for PCOS when they determine clinical benefit. This is legal, common, and supported by growing evidence. Many endocrinologists, reproductive endocrinologists, and functional medicine providers already prescribe GLP-1 therapy for PCOS patients, especially those with concurrent obesity or insulin resistance.
Insurance Coverage
Insurance coverage for GLP-1 medications prescribed for PCOS varies significantly. If you also have a type 2 diabetes or obesity diagnosis (BMI 30 or above, or BMI 27 or above with weight-related comorbidities), coverage is more likely. Some strategies that may help:
- Ask your provider to document all qualifying diagnoses, not just PCOS
- Request prior authorization with clinical justification
- Check manufacturer savings programs (Novo Nordisk and Eli Lilly both offer patient assistance)
- Explore compounded semaglutide as a lower-cost alternative
Telehealth Access
Telehealth platforms like 1st Optimal make it possible to consult with a provider experienced in both GLP-1 therapy and PCOS management from anywhere in the United States. The process typically involves:
- Initial consultation: A virtual visit to review symptoms, medical history, and goals
- Full lab work: At-home testing kits for hormone panels, metabolic markers, and insulin levels
- Personalized treatment plan: Your provider recommends the right medication, dose, and supporting interventions
- Ongoing monitoring: Regular check-ins, lab reviews, and dose adjustments as needed
This approach removes geographic barriers and gives women access to providers who actually understand the PCOS-GLP-1 connection, rather than relying on a PCP who may not be up to speed on the latest research.
Frequently Asked Questions
Can you take GLP-1 if you have PCOS?
Yes. GLP-1 medications can be prescribed off-label for women with PCOS. Research supports their use for improving insulin resistance, promoting weight loss, and reducing androgen levels. A qualified medical provider can evaluate whether GLP-1 therapy is appropriate based on your individual health profile and goals.
Does insurance cover GLP-1 for PCOS?
Coverage depends on your insurance plan and your full list of diagnoses. PCOS alone may not qualify, but if you also have obesity (BMI 30+) or type 2 diabetes, your chances of coverage increase significantly. Prior authorization with documented clinical justification is often required. Ask your provider to include all qualifying conditions when submitting.
Can GLP-1 help with PCOS symptoms beyond weight loss?
Research indicates that GLP-1 medications may improve multiple PCOS symptoms simultaneously. Published studies show reductions in insulin resistance markers (HOMA-IR), total testosterone levels, and waist circumference. One clinical study reported that 80% of participants normalized their menstrual cycles during semaglutide treatment. The improvements in androgen levels may also reduce symptoms like excess hair growth and acne over time.
How long does it take for GLP-1 to help PCOS symptoms?
Most women notice appetite reduction within the first 1-2 weeks. Measurable weight loss typically becomes apparent by 8-12 weeks. Improvements in insulin resistance and metabolic markers often appear within 3 months. Menstrual regularity and androgen-related symptoms like hirsutism may take 3-6 months to show meaningful change. Your provider will monitor lab work throughout treatment to track progress.
Can I take GLP-1 medications if I want to get pregnant?
GLP-1 medications are not recommended during pregnancy. However, using them before a planned pregnancy to improve metabolic health, reduce weight, and restore ovulatory cycles may improve your chances of conceiving once you stop the medication. Semaglutide should be discontinued at least 2 months before planned conception, and liraglutide at least 1 month before. Always discuss family planning with your provider before starting treatment.
Taking the Next Step
GLP-1 medications represent a meaningful addition to the PCOS treatment toolkit. The research is still developing, but the evidence so far points to real benefits for weight management, insulin resistance, hormonal balance, and menstrual regularity.
The key is working with a provider who understands both the medications and the broader picture of PCOS. A GLP-1 prescription alone is not a complete treatment plan. Combined with proper testing, nutritional support, exercise, and ongoing monitoring, these medications may help you break out of the cycle that has kept your symptoms from improving.
At 1st Optimal, our functional medicine providers work with women across all 50 states through our telehealth platform. We combine advanced diagnostic testing, personalized GLP-1 protocols, and root-cause hormone optimization to address PCOS from every angle.
Book your free women’s health consultation today to discuss whether GLP-1 therapy could be part of your personalized PCOS management plan.
